Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairm...(f them are beyond our control. For a fu...)

Date:2/26/2009

f them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

Use of non-GAAP Financial Information

A reconciliation of the Company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the Company's use of these non-GAAP measures, is included in the exhibits attached to this press release.

    CONTACT:

    Paul Donovan
    508-650-8541 (office)
    508-667-5165 (mobile)
    Media Relations
    Boston Scientific Corporation

    Larry Neumann
    508-650-8696 (office)
    Investor Relations
    Boston Scientific Corporation

                           BOSTON SCIENTIFIC CORPORATION
       NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS
                               (Unaudited)

                                    Three Months Ended December 31, 2008

                                         Previously            As Updated
                                          Reported
                                        Net       Impact     Net      Impact
                                      (loss)   
'/>"/>
SOURCE  Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 
Related biology technology :

1. Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
2. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
3. Boston Scientific Acquires Labcoat Limited
4. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
5. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
6. Boston Scientific to Participate in Piper Jaffray Health Care Conference
7. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
8. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
9. FDA Approves Boston Scientifics Apex(TM) PTCA Dilatation Catheter
10. InterMune to Present at Deutsche Bank Biotech Boston Confab
11. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability